Bladder Cancer Market Report and Forecast 2024-2032

Bladder Cancer Market Overview

Bladder cancer occurs in the lining of the bladder and is usually found in older adults. Recent data indicates that around 9 in 10 individuals with this cancer are aged 55 years and above, with the average age of diagnosis estimated to be 73 years. Further, studies reveal that 1 in 28 men will develop this cancer in their lifetime. On the other hand, 1 in 89 women have the likelihood of developing bladder cancer. The increasing prevalence of bladder cancer, especially in aging populations, is a primary driver of the market. The rising introduction of advanced diagnostic techniques and expansion of treatment options are expected to fuel the market growth. Moreover, the growing awareness about bladder cancer symptoms and risk factors, the rising investment in clinical trials, and the development of novel therapies are some of the factors poised to influence the market dynamics.

Bladder Cancer Market Growth Drivers

Increasing Prevalence of Bladder Cancer to Boost Market Growth

Bladder cancer accounts for 4% of cancers in the United States. Although reported to be less common in women, bladder cancer ranks as the fourth most common cancer in men. According to the American Cancer Society, nearly 83,190 new cases of bladder cancer and 16,840 deaths are estimated to occur in the United States in 2024. The increasing prevalence of bladder cancer and rising exposure to risk factors associated with this cancer are anticipated to boost the market growth.

Bladder Cancer Market Trends

Bladder Cancer Market Segmentation

Bladder Cancer Market Share

Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth

The market segmentation for treatment types includes chemotherapy, radiation therapy, immunotherapy, targeted drug therapy, and others. The immunotherapy segment is generating significant demand as it helps boost the immune system of the patient to fight cancer. It is especially recommended for bladder cancer patients who have not responded to chemotherapy. The rising development of new immunotherapeutic agents and the increasing research into combination therapies are anticipated to fuel the growth of the segment in the coming years.

Bladder Cancer Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share owing to the high incidence of bladder cancer, greater accessibility to advanced diagnostic tools and treatment options, and growing healthcare spending. The market also benefits from the presence of favorable reimbursement policies for cancer treatments and significant investment in clinical research and trials. Moreover, the rising demand for immunotherapies and personalized medicine and robust government support for cancer research are expected to bolster the market growth in the region.

Leading Players in the Bladder Cancer Market

The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

AstraZeneca

British-Swedish multinational pharmaceutical industry company AstraZeneca has a prominent presence in the market and is known for its robust oncology portfolio which includes medications for various types of cancer, including bladder cancer. In June 2024, the findings from the NIAGARA Phase III trial revealed that AstraZeneca’s Imfinzi (durvalumab) when used in combination with chemotherapy showed statistically significant improvement in event-free survival as well as overall survival for muscle-invasive bladder cancer.

Pfizer, Inc.

Pfizer, headquartered in New York, United States, is a major player in the market and is actively involved in ...

Novartis AG

Novartis, based in Basel, Switzerland, is an innovative medicines company, which is well-recognized for its co...

Amgen Inc.

Amgen, headquartered in Thousand Oaks, California, is counted as one of the world's largest independent biotec...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other key players in the market include F-Hoffmann-La Roche Ltd, GSK plc, Eli Lilly and Company, AbbVie Inc., and Teva Pharmaceuticals Ltd.

Key Questions Answered in the Bladder Cancer Market Report

• What was the bladder cancer market value in 2023?
• What is the bladder cancer market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on treatment type?
• What is the market breakup based on cancer type?
• Who are the major end users in the market?
• What are the major factors aiding the bladder cancer market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• How does the prevalence and incidence of bladder cancer affect the market landscape?
• What are the major bladder cancer market trends?
• How does the advancement in treatment options impact the market size?
• Which treatment type will dominate the market share?
• Which cancer type is expected to have a high market value in the coming years?
• Which end user is projected to contribute to the highest market growth?
• Who are the key players involved in the bladder cancer market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?